30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Travere Therapeutics Inc (TVTX)

Track

Over the last 90 days, Travere Therapeutics Inc. has seen significant insider selling, with a net value of over $1.6 million. Executives have been the primary sellers, contributing to a negative net insider count. Recent transactions include planned and proposed sales by directors and officers, occurring around the time of the last earnings report.
Stock chart
Ticker: TVTX Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Coughlin Timothy
2 sales — total 200,000 USD
Planned sale 12 Jun 2026
Value US$2,651,857.88 | Price 371.30 | Shares 89,995
Proposed sale 12 Jun 2026
Value US$207,485.99 | Price 29.50 | Shares 18,777
Planned sale 12 Jun 2026
Value US$3,483,998.71 | Price 347.44 | Shares 23,810
Proposed sale 12 Jun 2026
Value US$100,000.00 | Price 50.00 | Shares 1,000
Planned sale 15 May 2026
Value US$141,342.50 | Price 43.49 | Shares 3,250
Proposed sale 15 May 2026
Value US$141,182.59 | Price 43.44 | Shares 3,250
Planned sale 6 May 2026
Value US$988,875.00 | Price 43.95 | Shares 22,500
Proposed sale 6 May 2026
Value US$988,875.00 | Price 43.95 | Shares 22,500
Planned sale 6 May 2026
Value US$121,433.85 | Price 43.95 | Shares 2,763
Proposed sale 6 May 2026
Value US$121,433.85 | Price 43.95 | Shares 2,763
Planned sale 6 May 2026
Value US$13,668.45 | Price 43.95 | Shares 311
Planned sale 6 May 2026
Value US$13,624.50 | Price 43.95 | Shares 310
Planned sale 6 May 2026
Value US$91,240.20 | Price 43.95 | Shares 2,076
Proposed sale 6 May 2026
Value US$13,624.50 | Price 43.95 | Shares 310
Proposed sale 6 May 2026
Value US$13,668.45 | Price 43.95 | Shares 311
Proposed sale 6 May 2026
Value US$91,240.20 | Price 43.95 | Shares 2,076
Planned sale 5 May 2026
Value US$209,925.00 | Price 46.65 | Shares 4,500
Sale 5 May 2026
Value US$101,417.10 | Price 46.65 | Shares 2,174
Sale 5 May 2026
Value US$101,417.10 | Price 46.65 | Shares 2,174
Sale 5 May 2026
Value US$101,743.65 | Price 46.65 | Shares 2,181
Sale 5 May 2026
Value US$101,417.10 | Price 46.65 | Shares 2,174
Proposed sale 5 May 2026
Value US$101,743.65 | Price 46.65 | Shares 2,181
Proposed sale 5 May 2026
Value US$101,417.10 | Price 46.65 | Shares 2,174
Proposed sale 5 May 2026
Value US$101,417.10 | Price 46.65 | Shares 2,174
Proposed sale 5 May 2026
Value US$101,417.10 | Price 46.65 | Shares 2,174
Proposed sale 5 May 2026
Value US$209,925.00 | Price 46.65 | Shares 4,500
Planned sale 4 May 2026
Value US$900,000.00 | Price 45.00 | Shares 20,000
Planned sale 4 May 2026
Value US$360,000.00 | Price 45.00 | Shares 8,000
Planned sale 4 May 2026
Value US$900,000.00 | Price 45.00 | Shares 20,000
Proposed sale 4 May 2026
Value US$900,000.00 | Price 45.00 | Shares 20,000
Proposed sale 4 May 2026
Value US$360,000.00 | Price 45.00 | Shares 8,000
Proposed sale 4 May 2026
Value US$900,000.00 | Price 45.00 | Shares 20,000
Planned sale 1 May 2026
Value US$431,145.00 | Price 44.22 | Shares 9,750
Proposed sale 1 May 2026
Value US$431,145.00 | Price 44.22 | Shares 9,750
Planned sale 22 Apr 2026
Value US$355,719.00 | Price 39.09 | Shares 9,100
Proposed sale 22 Apr 2026
Value US$355,719.00 | Price 39.09 | Shares 9,100
Planned sale 15 Apr 2026
Value US$853.20 | Price 42.66 | Shares 20
Planned sale 15 Apr 2026
Value US$299,138.75 | Price 41.75 | Shares 7,165
Planned sale 15 Apr 2026
Value US$2,329,983.15 | Price 41.01 | Shares 56,815
Proposed sale 15 Apr 2026
Value US$2,629,832.99 | Price 41.09 | Shares 64,000
Planned sale 15 Apr 2026
Value US$43,206.54 | Price 42.61 | Shares 1,014
Planned sale 15 Apr 2026
Value US$66,304.27 | Price 42.53 | Shares 1,559
Planned sale 15 Apr 2026
Value US$217,506.12 | Price 41.62 | Shares 5,226
Planned sale 15 Apr 2026
Value US$43,376.98 | Price 42.61 | Shares 1,018
Proposed sale 15 Apr 2026
Value US$283,823.34 | Price 41.83 | Shares 6,785
Proposed sale 15 Apr 2026
Value US$43,206.54 | Price 42.61 | Shares 1,014
Proposed sale 15 Apr 2026
Value US$43,376.98 | Price 42.61 | Shares 1,018
Planned sale 14 Apr 2026
Value US$902,595.39 | Price 41.07 | Shares 21,977
Planned sale 14 Apr 2026
Value US$284,310.00 | Price 42.12 | Shares 6,750
Planned sale 14 Apr 2026
Value US$1,067,820.00 | Price 41.07 | Shares 26,000
Planned sale 14 Apr 2026
Value US$328,560.00 | Price 41.07 | Shares 8,000
Sale 14 Apr 2026
Value US$302,516.29 | Price 41.93 | Shares 7,215
Sale 14 Apr 2026
Value US$303,522.58 | Price 41.93 | Shares 7,239
Planned sale 14 Apr 2026
Value US$369.63 | Price 41.07 | Shares 9
Sale 14 Apr 2026
Value US$302,516.29 | Price 41.93 | Shares 7,215
Planned sale 14 Apr 2026
Value US$1,540,125.00 | Price 41.07 | Shares 37,500
Sale 14 Apr 2026
Value US$302,516.29 | Price 41.93 | Shares 7,215
Proposed sale 14 Apr 2026
Value US$302,515.98 | Price 41.93 | Shares 7,215
Proposed sale 14 Apr 2026
Value US$302,515.98 | Price 41.93 | Shares 7,215
Proposed sale 14 Apr 2026
Value US$302,515.98 | Price 41.93 | Shares 7,215
Proposed sale 14 Apr 2026
Value US$303,522.27 | Price 41.93 | Shares 7,239
Proposed sale 14 Apr 2026
Value US$245,600.00 | Price 30.70 | Shares 8,000
Proposed sale 14 Apr 2026
Value US$369.63 | Price 41.07 | Shares 9
Proposed sale 14 Apr 2026
Value US$1,540,125.00 | Price 41.07 | Shares 37,500
Proposed sale 14 Apr 2026
Value US$1,352,130.00 | Price 41.29 | Shares 32,750
Proposed sale 14 Apr 2026
Value US$902,595.39 | Price 41.07 | Shares 21,977
Sale 13 Apr 2026
Value US$1,875.25 | Price 28.85 | Shares 65
Proposed sale 13 Apr 2026
Value US$1,875.25 | Price 28.85 | Shares 65
Planned sale 6 Apr 2026
Value US$330,000.00 | Price 33.00 | Shares 10,000
Proposed sale 6 Apr 2026
Value US$330,000.00 | Price 33.00 | Shares 10,000
Planned sale 1 Apr 2026
Value US$300,000.00 | Price 30.00 | Shares 10,000
Planned sale 1 Apr 2026
Value US$300,000.00 | Price 30.00 | Shares 10,000
Planned sale 1 Apr 2026
Value US$789,583.08 | Price 31.46 | Shares 25,098
Planned sale 1 Apr 2026
Value US$1,066,256.10 | Price 30.55 | Shares 34,902
Proposed sale 1 Apr 2026
Value US$1,855,654.74 | Price 30.93 | Shares 60,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-16 2026-06-12 PlS Planned sale
1.2
Coughlin Timothy
Non-Executive Director
89,995 -39.6%
371.30
US$2,651,858 		89,995 -39.6% 371.30 US$2,651,858
2026-06-16 2026-06-12 PlS Planned sale
0.5
Baynes Roy D.
Non-Executive Director
23,810 +24.7%
347.44
US$3,483,999 		23,810 +24.7% 347.44 US$3,483,999
2026-06-12 2026-06-12 PrS Proposed sale
0.5
ROY BAYNES

Director

Non-Executive Director
54,170
161.52
US$2,410,536 		54,170 161.52 US$2,410,536
2026-06-12 2026-06-12 PrS Proposed sale
1.2
Coughlin Timothy

Director

Non-Executive Director
1,000
50.04
US$100,000 		1,000 50.04 US$100,000
2026-05-19 2026-05-15 PlS Planned sale
1.2
Coughlin Timothy
Non-Executive Director
3,250 -5.9%
43.49
US$141,342 		3,250 -5.9% 43.49 US$141,342
2026-05-15 2026-05-15 PrS Proposed sale
1.2
Coughlin Timothy

Director

Non-Executive Director
3,250
43.44
US$141,183 		3,250 43.44 US$141,183
2026-05-06 2026-05-06 PlS Planned sale
2.7
Dube Eric M

CHIEF EXECUTIVE OFFICER

Executive Director
22,500 -4.9%
43.95
US$988,875 		22,500 -4.9% 43.95 US$988,875
2026-05-06 2026-05-06 PlS Planned sale
2.3
ROTE WILLIAM E.

Chief Research Officer

Officer
2,763 -2.3%
43.95
US$121,434 		2,763 -2.3% 43.95 US$121,434
2026-05-06 2026-05-06 PlS Planned sale
2.7
Inrig Jula

CHIEF MEDICAL OFFICER

Officer
311 -0.3%
43.95
US$13,668 		311 -0.3% 43.95 US$13,668
2026-05-06 2026-05-06 PlS Planned sale
2.8
Cline Christopher R.

CHIEF FINANCIAL OFFICER

Officer
310 -0.3%
43.95
US$13,624 		310 -0.3% 43.95 US$13,624
2026-05-06 2026-05-06 PlS Planned sale
2.4
REED ELIZABETH E

Chief Legal Officer and GC

Officer
2,076 -1.9%
43.95
US$91,240 		2,076 -1.9% 43.95 US$91,240
2026-05-06 2026-05-06 PrS Proposed sale
2.8
CHRISTOPHER CLINE

Officer

Officer
310
43.95
US$13,624 		310 43.95 US$13,624
2026-05-06 2026-05-06 PrS Proposed sale
2.7
JULA INRIG

Officer

Officer
311
43.95
US$13,668 		311 43.95 US$13,668
2026-05-06 2026-05-06 PrS Proposed sale
2.4
ELIZABETH REED

Officer

Officer
2,076
43.95
US$91,240 		2,076 43.95 US$91,240
2026-05-06 2026-05-06 PrS Proposed sale
2.7
Dube Eric M

Officer

Officer
22,500
43.95
US$988,875 		22,500 43.95 US$988,875
2026-05-06 2026-05-06 PrS Proposed sale
2.3
ROTE WILLIAM E.

Officer

Officer
2,763
43.95
US$121,434 		2,763 43.95 US$121,434
2026-05-06 2026-05-05 PlS Planned sale
0.5
Baynes Roy D.
Non-Executive Director
4,500 -10.7%
46.65
US$209,925 		4,500 -10.7% 46.65 US$209,925
2026-05-06 2026-05-05 S Sale
2.7
Inrig Jula

CHIEF MEDICAL OFFICER

Officer
2,174 -1.9%
46.65
US$101,417 		2,174 -1.9% 46.65 US$101,417
2026-05-06 2026-05-05 S Sale
2.9
Heerma Peter

CHIEF COMMERCIAL OFFICER

Officer
2,174 -1.5%
46.65
US$101,417 		2,174 -1.5% 46.65 US$101,417
2026-05-06 2026-05-05 S Sale
2.8
Cline Christopher R.

CHIEF FINANCIAL OFFICER

Officer
2,181 -1.8%
46.65
US$101,744 		2,181 -1.8% 46.65 US$101,744
2026-05-06 2026-05-05 S Sale
2.4
REED ELIZABETH E

Chief Legal Officer and GC

Officer
2,174 -2.0%
46.65
US$101,417 		2,174 -2.0% 46.65 US$101,417
2026-05-05 2026-05-05 PrS Proposed sale
2.8
Christopher Cline

Officer

Officer
2,181
46.65
US$101,744 		2,181 46.65 US$101,744
2026-05-05 2026-05-05 PrS Proposed sale
2.4
Elizabeth E. Reed

Officer

Officer
2,174
46.65
US$101,417 		2,174 46.65 US$101,417
2026-05-05 2026-05-05 PrS Proposed sale
2.9
Peter Heerma

Officer

Officer
2,174
46.65
US$101,417 		2,174 46.65 US$101,417
2026-05-05 2026-05-05 PrS Proposed sale
2.7
Jula Inrig

Officer

Officer
2,174
46.65
US$101,417 		2,174 46.65 US$101,417
2026-05-05 2026-05-05 PrS Proposed sale
0.5
ROY BAYNES

Director

Non-Executive Director
4,500
46.65
US$209,925 		4,500 46.65 US$209,925
2026-05-06 2026-05-04 PlS Planned sale
2.7
Inrig Jula

CHIEF MEDICAL OFFICER

Officer
20,000 -15.2%
45.00
US$900,000 		20,000 -15.2% 45.00 US$900,000
2026-05-06 2026-05-04 PlS Planned sale
1.9
Meckler Jeffrey A
Non-Executive Director
8,000 -8.4%
45.00
US$360,000 		8,000 -8.4% 45.00 US$360,000
2026-05-06 2026-05-04 PlS Planned sale
2.4
REED ELIZABETH E

Chief Legal Officer and GC

Officer
20,000 -16.0%
45.00
US$900,000 		20,000 -16.0% 45.00 US$900,000
2026-05-04 2026-05-04 PrS Proposed sale
2.4
ELIZABETH REED

Officer

Officer
20,000
45.00
US$900,000 		20,000 45.00 US$900,000
2026-05-04 2026-05-04 PrS Proposed sale
1.9
JEFFREY MECKLER

Director

Non-Executive Director
8,000
45.00
US$360,000 		8,000 45.00 US$360,000
2026-05-04 2026-05-04 PrS Proposed sale
2.7
JULA INRIG

Officer

Officer
20,000
45.00
US$900,000 		20,000 45.00 US$900,000
2026-05-04 2026-05-01 PlS Planned sale
0.5
Baynes Roy D.
Non-Executive Director
9,750 -20.6%
44.22
US$431,145 		9,750 -20.6% 44.22 US$431,145
2026-05-01 2026-05-01 PrS Proposed sale
0.5
ROY BAYNES

Director

Non-Executive Director
9,750
44.22
US$431,145 		9,750 44.22 US$431,145
2026-04-23 2026-04-22 PlS Planned sale
2.3
ROTE WILLIAM E.

Chief Research Officer

Officer
9,100 -7.4%
39.09
US$355,719 		9,100 -7.4% 39.09 US$355,719
2026-04-22 2026-04-22 PrS Proposed sale
2.3
ROTE WILLIAM E.

Officer

Officer
9,100
39.09
US$355,719 		9,100 39.09 US$355,719
2026-04-15 2026-04-15 PlS Planned sale
2.7
Dube Eric M

CHIEF EXECUTIVE OFFICER

Executive Director
20 -0.0%
42.66
US$853 		20 -0.0% 42.66 US$853
2026-04-15 2026-04-15 PlS Planned sale
2.7
Dube Eric M

CHIEF EXECUTIVE OFFICER

Executive Director
7,165 -1.6%
41.75
US$299,139 		7,165 -1.6% 41.75 US$299,139
2026-04-15 2026-04-15 PlS Planned sale
2.7
Dube Eric M

CHIEF EXECUTIVE OFFICER

Executive Director
56,815 -11.4%
41.01
US$2,329,983 		56,815 -11.4% 41.01 US$2,329,983
2026-04-15 2026-04-15 PlS Planned sale
2.8
Cline Christopher R.

CHIEF FINANCIAL OFFICER

Officer
1,014 -0.9%
42.61
US$43,207 		1,014 -0.9% 42.61 US$43,207
2026-04-15 2026-04-15 PlS Planned sale
2.4
REED ELIZABETH E

Chief Legal Officer and GC

Officer
1,559 -1.5%
42.53
US$66,304 		1,559 -1.5% 42.53 US$66,304
2026-04-15 2026-04-15 PlS Planned sale
2.4
REED ELIZABETH E

Chief Legal Officer and GC

Officer
5,226 -4.7%
41.62
US$217,506 		5,226 -4.7% 41.62 US$217,506
2026-04-15 2026-04-15 PlS Planned sale
2.7
Inrig Jula

CHIEF MEDICAL OFFICER

Officer
1,018 -0.9%
42.61
US$43,377 		1,018 -0.9% 42.61 US$43,377
2026-04-15 2026-04-15 PrS Proposed sale
2.4
ELIZABETH REED

Officer

Officer
6,785
41.83
US$283,823 		6,785 41.83 US$283,823
2026-04-15 2026-04-15 PrS Proposed sale
2.7
Dube Eric M

Officer

Officer
64,000
41.09
US$2,629,833 		64,000 41.09 US$2,629,833
2026-04-15 2026-04-15 PrS Proposed sale
2.8
CHRISTOPHER CLINE

Officer

Officer
1,014
42.61
US$43,207 		1,014 42.61 US$43,207
2026-04-15 2026-04-15 PrS Proposed sale
2.7
JULA INRIG

Officer

Officer
1,018
42.61
US$43,377 		1,018 42.61 US$43,377
2026-04-16 2026-04-14 PlS Planned sale
2.9
Calvin Sandra

SVP, CHIEF ACCOUNTING OFFICER

Officer
21,977 -34.2%
41.07
US$902,595 		21,977 -34.2% 41.07 US$902,595
2026-04-16 2026-04-14 PlS Planned sale
0.5
Baynes Roy D.
Non-Executive Director
6,750 -15.3%
42.12
US$284,310 		6,750 -15.3% 42.12 US$284,310
2026-04-16 2026-04-14 PlS Planned sale
0.5
Baynes Roy D.
Non-Executive Director
26,000 -37.0%
41.07
US$1,067,820 		26,000 -37.0% 41.07 US$1,067,820
2026-04-16 2026-04-14 PlS Planned sale
2.2
LYONS GARY A
Non-Executive Director
8,000 -12.2%
41.07
US$328,560 		8,000 -12.2% 41.07 US$328,560
2026-04-15 2026-04-14 S Sale
2.9
Heerma Peter

CHIEF COMMERCIAL OFFICER

Officer
7,215 -4.9%
41.93
US$302,516 		7,215 -4.9% 41.93 US$302,516
2026-04-15 2026-04-14 S Sale
2.8
Cline Christopher R.

CHIEF FINANCIAL OFFICER

Officer
7,239 -5.8%
41.93
US$303,523 		7,239 -5.8% 41.93 US$303,523
2026-04-15 2026-04-14 PlS Planned sale
2.8
Cline Christopher R.

CHIEF FINANCIAL OFFICER

Officer
9 -0.0%
41.07
US$370 		9 -0.0% 41.07 US$370
2026-04-15 2026-04-14 S Sale
2.4
REED ELIZABETH E

Chief Legal Officer and GC

Officer
7,215 -6.1%
41.93
US$302,516 		7,215 -6.1% 41.93 US$302,516
2026-04-15 2026-04-14 PlS Planned sale
2.4
REED ELIZABETH E

Chief Legal Officer and GC

Officer
37,500 -23.9%
41.07
US$1,540,125 		37,500 -23.9% 41.07 US$1,540,125
2026-04-15 2026-04-14 S Sale
2.7
Inrig Jula

CHIEF MEDICAL OFFICER

Officer
7,215 -6.0%
41.93
US$302,516 		7,215 -6.0% 41.93 US$302,516
2026-04-14 2026-04-14 PrS Proposed sale
2.4
Elizabeth E. Reed

Officer

Officer
7,215
41.93
US$302,516 		7,215 41.93 US$302,516
2026-04-14 2026-04-14 PrS Proposed sale
2.7
Jula Inrig

Officer

Officer
7,215
41.93
US$302,516 		7,215 41.93 US$302,516
2026-04-14 2026-04-14 PrS Proposed sale
2.9
Peter Heerma

Officer

Officer
7,215
41.93
US$302,516 		7,215 41.93 US$302,516
2026-04-14 2026-04-14 PrS Proposed sale
2.8
Christopher Cline

Officer

Officer
7,239
41.93
US$303,522 		7,239 41.93 US$303,522
2026-04-14 2026-04-14 PrS Proposed sale
2.2
GARY A LYONS

Officer

Officer
8,000
30.70
US$245,600 		8,000 30.70 US$245,600
2026-04-14 2026-04-14 PrS Proposed sale
2.8
CHRISTOPHER CLINE

Officer

Officer
9
41.07
US$370 		9 41.07 US$370
2026-04-14 2026-04-14 PrS Proposed sale
2.4
ELIZABETH REED

Officer

Officer
37,500
41.07
US$1,540,125 		37,500 41.07 US$1,540,125
2026-04-14 2026-04-14 PrS Proposed sale
0.5
ROY BAYNES

Director

Non-Executive Director
32,750
41.29
US$1,352,130 		32,750 41.29 US$1,352,130
2026-04-14 2026-04-14 PrS Proposed sale
2.9
SANDRA CALVIN

Officer

Officer
21,977
41.07
US$902,595 		21,977 41.07 US$902,595
2026-04-15 2026-04-13 S Sale
2.8
Cline Christopher R.

CHIEF FINANCIAL OFFICER

Officer
65 -0.1%
28.85
US$1,875 		65 -0.1% 28.85 US$1,875
2026-04-13 2026-04-13 PrS Proposed sale
2.8
Christopher Cline

Officer

Officer
65
28.85
US$1,875 		65 28.85 US$1,875
2026-04-07 2026-04-06 PlS Planned sale
0.5
Baynes Roy D.
Non-Executive Director
10,000 -21.1%
33.00
US$330,000 		10,000 -21.1% 33.00 US$330,000
2026-04-06 2026-04-06 PrS Proposed sale
0.5
ROY BAYNES

Director

Non-Executive Director
10,000
33.00
US$330,000 		10,000 33.00 US$330,000
2026-04-02 2026-04-01 PlS Planned sale
2.4
REED ELIZABETH E

Chief Legal Officer and GC

Officer
10,000 -8.7%
30.00
US$300,000 		10,000 -8.7% 30.00 US$300,000
2026-04-02 2026-04-01 PlS Planned sale
2.4
REED ELIZABETH E

Chief Legal Officer and GC

Officer
10,000 -8.7%
30.00
US$300,000 		10,000 -8.7% 30.00 US$300,000
2026-04-02 2026-04-01 PlS Planned sale
2.7
Dube Eric M

CHIEF EXECUTIVE OFFICER

Executive Director
25,098 -5.5%
31.46
US$789,583 		25,098 -5.5% 31.46 US$789,583
2026-04-02 2026-04-01 PlS Planned sale
2.7
Dube Eric M

CHIEF EXECUTIVE OFFICER

Executive Director
34,902 -7.1%
30.55
US$1,066,256 		34,902 -7.1% 30.55 US$1,066,256
2026-04-01 2026-04-01 PrS Proposed sale
2.7
Dube Eric M

Officer; Director

Executive Director
60,000
30.93
US$1,855,655 		60,000 30.93 US$1,855,655
Explore more

More insider trading research around Travere Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America